Nogapendekin alfa inbakicept-pmln is approved by the USFDA for BCG-unresponsive non-muscle invasive bladder cancer

Nogapendekin alfa inbakicept-pmln with BCG for bladder cancer There is a type of bladder cancer called NMIBC that does not spread to the muscles. The Food and Drug Administration has approved the use of nogapendekin alfa inbakice..

High tumor burden, Immunotherapy, KEYTRUDA, Pembrolizumab, TMB-H

Pembrolizumab approved for use in any cancer with a high tumor mutational burden

July 2021: The US Food and Medication Administration (FDA) has expanded the indications for pembrolizumab (Keytruda), an immunotherapy drug, to encompass any cancer with a high mutational burden (TMB-H). The new authorization is f..

The culprit of the recurrence of bladder cancer "MLL gene" has been found

The research team of Shenzhen Hospital collected 37 samples of bladder cancer patients, performed whole exon sequencing and gene editing techniques, and discovered the culprit of bladder cancer recurrence-"MLL gene".On the 7th, th..

Acalabrutunib, Avelumab, CART therapy, Dabrafanib, Kymriah, Latest drugs, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA

Latest drugs in the treatment of cancer

July 2021: Check out the latest drugs in the treatment of cancer. Every year, after examining the trials and other important factors, the USFDA approves drugs, and thus cancer patients can now believe that a cure is very near. ..